Articles tagged with Myeloid Leukemia
A retrospective study of 110 elderly leukemia patients found similar complete remission and two-year survival rates as younger patients when treated with anthracyclin-based induction chemotherapy. The study's findings suggest that age is not a predictor of survival, but rather the treatment protocol received.
Researchers have identified two distinct patterns of gene activity that correlate with patient outcomes in intermediate-risk AML. The findings could lead to more personalized treatment approaches for patients with this type of cancer.
The calcium-sensing receptor plays a crucial role in regulating mammary gland function, influencing milk production and composition. This study demonstrates that the receptor helps match milk production with available calcium levels in the mother's body.
A recent study identified 35 genes that may be linked to prognosis in pediatric acute myeloid leukemia (AML), providing new insights into the disease. These unexpected genes were found independently of current classification methods and separated patients into high- and low-risk groups.
Research suggests that a mutation in a tyrosine kinase receptor gene, when combined with aml1-eto gene mutation, can cause acute myeloid leukemia in mice. This discovery raises the possibility of new treatments targeting these genes to control the disease.
Researchers induce leukemia cells to change behavior and stimulate immune system, killing significant numbers of leukemia cells in a 3-step process. The approach has shown strong killing effect against AML cell lines but not other types of cancer, with potential for safe transfer back into patients.
Two new drugs, PKC412 and CT53518, have shown promising results in treating acute myeloid leukemia (AML), a deadly form of blood cancer. The drugs, which target the FLT3 receptor, have been effective in killing leukemia cells and prolonging survival in mouse models.
Researchers have developed a new drug, CEP-701, that targets the genetic error causing a type of leukemia. The drug has shown promising results in clinical trials, interfering with the signal of the altered gene and leading to leukemia cell death.
The European Commission has designated Mylotarg as an orphan medicinal product for treating patients with CD33-positive relapsed acute myeloid leukemia. The compound represents a novel anticancer therapy and has shown promising results in clinical trials.
A clinical trial of Mylotarg found disease remission in 34% of patients under 60 and 26% of those over 60, with a median overall survival of 5.9 months. No significant differences were seen in adverse events between age groups.
Researchers developed CMA-676, an antibody-drug conjugate targeting AML cells while sparing normal blood cells. The treatment produces mild side effects and induces remission comparable to standard chemotherapy regimens.
Clinical trials show substantial increase in leukemia-free survival among AML patients treated with Maxamine Therapy. The treatment has been shown to prevent relapse and prolong remission while maintaining a good quality of life.
A new experimental compound, CMA-676, demonstrates promising efficacy in treating acute myelogenous leukemia (AML) with an antibody-targeted chemotherapy approach. The treatment shows a remission rate of approximately 40% comparable to standard combination chemotherapy regimens.
A 15-year study of 628 AML patients confirms that chromosomal abnormalities can predict treatment success and likelihood of cure. Patients with specific genetic markers tend to have better outcomes, while those without them face poorer survival rates.
Researchers discovered a genetic defect in ALL1 gene duplication that signals poor prognosis and shorter survival time in AML patients. Patients with this defect require aggressive treatment, including allogenic bone marrow transplant, to improve survival rates.